[Drug therapy and nutrition therapy of a young patient with Crohn disease].
Verkasalo
Matti
M
HUS:n lasten ja nuorten sairaala, Lastenklinikka PL 281, 00029 HUS. matti.verkasalo@hus.fi
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001691:Biological Therapy; D002113:Calcification, Physiologic / Q000187:drug effects; D002648:Child; D003424:Crohn Disease / Q000150:complications / Q000178:diet therapy / Q000628:therapy*; D004750:Enteral Nutrition / Q000379:methods*; D006130:Growth Disorders / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D000069285:Infliximab; D009748:Nutrition Disorders / Q000209:etiology / Q000517:prevention & control; D009747:Nutritional Physiological Phenomena; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control; D019936:Probiotics / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D001379:Azathioprine